Pfizer endorses CanSino's meningitis vaccine, giving Chinese biotech company a shot in the arm - (South China Morning Post via NewsPoints Desk)

  • CanSino Biologics has signed an agreement under which Pfizer will promote its meningitis vaccine candidate Menhycia in China, reported South China Morning Post.

  • “The agreement paves a way for a deepened tie-up with [Pfizer] and strengthens our commercial capabilities,” said Yu Xuefeng, chairman of CanSino. “It also lays a solid foundation for CanSino to consolidate a foothold in China while going international.”

  • According to pharmaceutical executives, the endorsement is significant after China was hit by a scandal that triggered a crisis of confidence in the domestic vaccine industry. In 2018, it was found that Changchun Changsheng Bio-technology supplied ineffective DPT vaccines and forged data on its rabies vaccine production procedures. 

  • The NMPA has said it will prioritize the review of Menhycia, signalling that it would receive approval soon.

To read more NewsPoints articles, click here.